Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs AMC ENTERTAINMENT HOLDINGS, INC. (AMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs AMC ENTERTAINMENT HOLDINGS, INC. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while AMC ENTERTAINMENT HOLDINGS, INC. trades at $1.88 (market cap $1.69B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 23.6× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | AMC | |
|---|---|---|
Market Cap | $39.89B | $1.69B |
Sector | Health | Media |
52-Week High | $491.22 | $3.54 |
52-Week Low | $278.09 | $0.95 |
Enterprise Value | $38.15B | $9.28B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
AMC trades at $1.89, down 0.53% on the day, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q1 2026 EPS of -$0.36, missing expectations, while revenue trends show modest growth from $4.6B in 2024 to $4.85B in 2025. Recent news highlights box office recovery optimism and a $200 million stock offering that caused dilution concerns.
Outlook remains challenging with persistent net losses and high debt burden, though analyst consensus targets $1.90 with 32% buy ratings. Key risks include ongoing dilution from equity offerings, competitive pressures in entertainment, and the need for sustained box office recovery to improve cash flow and profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →
